Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor

Summary. Dental extraction in patients with haemophilia A and high‐titre inhibitor is always a high‐risk procedure, which often presents a lot of problems associated with bleeding. Prothrombin complex concentrates or recombinant activated factor VII (rFVIIa) has been used to control bleeding. rFVIIa was administered to five boys with severe haemophilia A complicated with inhibitor, who underwent seven dental extractions. The age of the patients ranged between 8 and 13 years (median 10 years). The concentrate was administered in doses of 90–100 μ g kg −1 body weight. Duration in the therapy and intervals between rFVIIa doses depended on the severity of bleeding. rFVIIa was proven to be highly effective and no side‐effects of the product were observed.